相关实验视频

Updated: May 13, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

用于循环素依赖性激酶9 (CDK9) 抑制剂的药物设计在中

Kaori Asamitsu¹, Takatsugu Hirokawa^2,3, Takashi Okamoto¹

¹Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Aichi, Japan.

Biochemistry and biophysics reports

|April 15, 2025

概括

研究人员发现了针对循环素依赖激酶9 (CDK9) 中隐藏的空洞的新型化合物,这对癌症和艾滋病毒至关重要. 将这些与现有的抑制剂结合起来,显示出附加效应,为CDK9相关疾病提供了新的治疗策略.

科学领域:

生物化学生物化学
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

循环素依赖性激酶9 (CDK9) 是恶性瘤和HIV复制的潜在治疗点.
到目前为止,还没有开发出有效的CDK9抑制剂.
以前的分子动力学 (MD) 模拟揭示了CDK9.9中的一个隐藏的空洞.

研究的目的:

为了识别针对CDK9.9中隐藏的腔体的新型化合物.
评估已识别的化合物对CDK9/CyclinT1复合物的抑制作用.
评估新型化合物与现有CDK抑制剂的组合效应.

主要方法:

化学信息学分析以确定与已知的CDK9抑制剂相似的化合物.
分子动力学 (MD) 模拟以描述CDK9隐藏腔的特征.
在体外测试以确认对CDK9/CyclinT1复合体的抑制作用.

主要成果:

确定了针对CDK9隐藏腔的CCII和CCIII区域的新型化合物.
这些化合物在体外对CDK9/CyclinT1复合体表现出抑制作用.
与已知抑制剂BS-181的联合治疗显示了对CDK9表达的附加抑制.

结论:

这项研究证实了CDK9.9中存在一种暂时暴露的隐藏腔的存在.
针对这种腔的已识别的化合物显示出CDK9抑制剂开发的前景.
组合策略可能会增强对CDK9依赖性疾病的治疗疗效.

关键词:

循环素依赖激酶 (CDK) 9 循环素依赖激酶在形药物设计中.激酶抑制剂激酶抑制剂分子对接是分子对接.

更多相关视频

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Anaphase Promoting Complex

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...